Improved Biochemical Outcomes With Statin Use in Patients With High-Risk Localized Prostate Cancer Treated With Radiotherapy


      To investigate the association between 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and biochemical and survival outcomes after high-dose radiotherapy (RT) for prostate cancer.

      Methods and Materials

      A total of 1711 men with clinical stage T1–T3 prostate cancer were treated with conformal RT to a median dose of 81 Gy during 1995–2007. Preradiotherapy medication data were available for 1681 patients. Three hundred eighty-two patients (23%) were taking a statin medication at diagnosis and throughout RT. Nine hundred forty-seven patients received a short-course of neoadjuvant and concurrent androgen-deprivation therapy (ADT) with RT. The median follow-up was 5.9 years.


      The 5- and 8-year PSA relapse-free survival (PRFS) rates for statin patients were 89% and 80%, compared with 83% and 74% for those not taking statins (p = 0.002). In a multivariate analysis, statin use (hazard ratio [HR] 0.69, p = 0.03), National Comprehensive Cancer Network (NCCN) low-risk group, and ADT use were associated with improved PRFS. Only high-risk patients in the statin group demonstrated improvement in PRFS (HR 0.52, p = 0.02). Across all groups, statin use was not associated with improved distant metastasis-free survival (DMFS) (p = 0.51). On multivariate analysis, lower NCCN risk group (p = 0.01) and ADT use (p = 0.005) predicted improved DMFS.


      Statin use during high-dose RT for clinically localized prostate cancer was associated with a significant improvement in PRFS in high-risk patients. These data suggest that statins have anticancer activity and possibly provide radiosensitization when used in conjunction with RT in the treatment of prostate cancer.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Goldstein J.L.
        • Brown M.S.
        Regulation of the mevalonate pathway.
        Nature. 1990; 343: 425-430
        • Jackson S.M.
        • Ericsson J.
        • Edwards P.A.
        Signaling molecules derived from the cholesterol biosynthetic pathway.
        Subcell Biochem. 1997; 28: 1-21
        • Graaf M.R.
        • Richel D.J.
        • van Noorden C.J.
        • et al.
        Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
        Cancer Treat Rev. 2004; 30: 609-641
        • Kaye J.A.
        • Jick H.
        Statin use and cancer risk in the General Practice Research Database.
        Br J Cancer. 2004; 90: 635-637
        • Blais L.
        • Desgagne A.
        • LeLorier J.
        3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study.
        Arch Intern Med. 2000; 160: 2363-2368
        • Poynter J.N.
        • Gruber S.B.
        • Higgins P.D.
        • et al.
        Statins and the risk of colorectal cancer.
        N Engl J Med. 2005; 352: 2184-2192
        • Katz M.S.
        Therapy insight: Potential of statins for cancer chemoprevention and therapy.
        Natl Clin Pract Oncol. 2005; 2: 82-89
        • Wong W.W.
        • Dimitroulakos J.
        • Minden M.D.
        • et al.
        HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis.
        Leukemia. 2002; 16: 508-519
        • Ukomadu C.
        • Dutta A.
        Inhibition of cdk2 activating phosphorylation by mevastatin.
        J Biol Chem. 2003; 278: 4840-4846
        • Borner M.M.
        • Myers C.E.
        • Sartor O.
        • et al.
        Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3.
        Cancer Res. 1995; 55: 2122-2128
        • Park C.
        • Lee I.
        • Kang W.K.
        Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death.
        Carcinogenesis. 2001; 22: 1727-1731
        • Agarwal B.
        • Bhendwal S.
        • Halmos B.
        • et al.
        Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
        Clin Cancer Res. 1999; 5: 2223-2229
        • Park H.J.
        • Kong D.
        • Iruela-Arispe L.
        • et al.
        3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
        Circ Res. 2002; 91: 143-150
        • Laufs U.
        • La Fata V.
        • Plutzky J.
        • et al.
        Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
        Circulation. 1998; 97: 1129-1135
        • Hernandez-Perera O.
        • Perez-Sala D.
        • Navarro-Antolin J.
        • et al.
        Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
        J Clin Invest. 1998; 101: 2711-2719
        • Katz M.S.
        • Minsky B.D.
        • Saltz L.B.
        • et al.
        Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
        Int J Radiat Oncol Biol Phys. 2005; 62: 1363-1370
        • Kawata S.
        • Yamasaki E.
        • Nagase T.
        • et al.
        Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
        Br J Cancer. 2001; 84: 886-891
        • Tsai H.K.
        • Katz M.S.
        • Coen J.J.
        • et al.
        Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
        Urology. 2006; 8: 1188-1192
        • Scardino P.
        Update: NCCN prostate cancer Clinical Practice Guidelines.
        J Natl Compr Canc Netw. 2005; 3: S29-S33
        • Zelefsky M.J.
        • Fuks Z.
        • Happersett L.
        • et al.
        Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.
        Radiother Oncol. 2000; 55: 241-249
        • Ling C.C.
        • Burman C.
        • Chui C.S.
        • et al.
        Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation.
        Int J Radiat Oncol Biol Phys. 1996; 35: 721-730
        • Burman C.
        • Chui C.S.
        • Kutcher G.
        • et al.
        Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: A strategy for large-scale implementation for the treatment of carcinoma of the prostate.
        Int J Radiat Oncol Biol Phys. 1997; 39: 863-873
        • Roach 3rd, M.
        • Hanks G.
        • Thames Jr., H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Kaplan E.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Cox D.
        Regression models and life tables.
        J R Stat Soc B. 1972; 34 ([discussion]): 187-220
        • Shannon J.
        • Tewoderos S.
        • Garzotto M.
        • et al.
        Statins and prostate cancer risk: A case-control study.
        Am J Epidemiol. 2005; 162: 318-325
        • Graaf M.R.
        • Beiderbeck A.B.
        • Egberts A.C.
        • et al.
        The risk of cancer in users of statins.
        J Clin Oncol. 2004; 22: 2388-2394
        • Platz E.A.
        • Leitzmann M.F.
        • Visvanathan K.
        • et al.
        Statin drugs and risk of advanced prostate cancer.
        J Natl Cancer Inst. 2006; 98: 1819-1825
        • Jacobs E.J.
        • Rodriguez C.
        • Bain E.B.
        • et al.
        Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort.
        Cancer Epidemiol Biomarkers Prev. 2007; 16: 2213-2217
        • Flick E.D.
        • Habel L.A.
        • Chan K.A.
        • et al.
        Statin use and risk of prostate cancer in the California Men's Health Study cohort.
        Cancer Epidemiol Biomarkers Prev. 2007; 16: 2218-2225
        • Murtola T.J.
        • Tammela T.L.
        • Lahtela J.
        • et al.
        Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study.
        Cancer Epidemiol Biomarkers Prev. 2007; 16: 2226-2232
        • Bonovas S.
        • Filioussi K.
        • Sitaras N.M.
        Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies.
        Int J Cancer. 2008; 123: 899-904
        • Moyad M.A.
        • Merrick G.S.
        • Butler W.M.
        • et al.
        Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
        Urology. 2005; 66: 1150-1154
        • Soto D.E.
        • Daignault S.
        • Sandler H.M.
        • et al.
        No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer.
        Urology. 2009; 73: 158-162
        • Zelefsky M.J.
        • Yamada Y.
        • Fuks Z.
        • et al.
        Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
        Int J Radiat Oncol Biol Phys. 2008; 71: 1028-1033
        • Kuban D.A.
        • Tucker S.L.
        • Dong L.
        • et al.
        Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 67-74
        • Jacobs R.
        • Hanlon A.L.
        • Horwitz E.M.
        • et al.
        The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
        Cancer. 2004; 100: 538-543
        • Pound C.R.
        • Partin A.W.
        • EIsenberger M.A.
        • et al.
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591-1597
        • Hamilton R.J.
        • Goldberg K.C.
        • Platz E.A.
        • et al.
        The influence of statin medications on prostate-specific antigen levels.
        J Natl Cancer Inst. 2008; 100: 1511-1518
        • Weis M.
        • Heeschen C.
        • Glassford A.J.
        • et al.
        Statins have biphasic effects on angiogenesis.
        Circulation. 2002; 105: 73-745
        • Sivaprasad U.
        • Abbas T.
        • Dutta A.
        Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
        Mol Canc Ther. 2006; 5: 2310-2316


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.